PACB Pacific Biosciences of California, Inc.

NASDAQ
$1.15

Pacific Biosciences of California, Inc. (PACB) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.5% since its last earnings release on August 5, 2026.

Pacific Biosciences of California Reported In-line with Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.13)
Rev est $42.9M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.15

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc., is engaged in design, development and commercialization of innovative tools for biological research. The Company' products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS.

Sector

Technology

Industry

Scientific / Technical Instruments